

Product Data Sheet

Product Name: Tivanisiran sodium

Cat. No.: GC70676

Chemical Properties

Cas. No. 1848239-71-3

Formula $C_{361}H_{411}N_{141}O_{262}Na_{36}P_{36}$ M.Wt 12859.67

Solubility Storage -20°C, sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

Tivanisiran (sodium)

Background

Tivanisiran sodium is a small interfering RNA (siRNA) drug with topical ophthalmic activity that targets and induces the degradation of TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) mRNA. Tivanisiran sodium can be used in research related to Sjögren's syndrome-associated dry eye^[1-4].

References:

[1] Moreno-Montañés J, Bleau AM, Jimenez AI. Tivanisiran sodium, a novel siRNA for the treatment

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.

[2] Patil S, Sawale G, Ghuge S, et al. Quintessence of currently approved and upcoming treatments for dry eye disease. Graefes Arch Clin Exp Ophthalmol. 2025 Feb;263(2):269-278.

[3] Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol. 2021 Jul;189:114432.

[4] Baiula M, Spampinato S. Experimental Pharmacotherapy for Dry Eye Disease: A Review. J Exp Pharmacol. 2021 Mar 23;13:345-358.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA